HealthCare Global Enterprises Concall Update: Margin Targets and Expansion Plans

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights

HealthCare Global Enterprises released its Q1 FY27 earnings call transcript, with management guiding for mid-teens revenue growth and EBITDA margins of 21-22% in two years and 25% in four to five years. Annual maintenance CapEx is targeted at ~INR 100 crores, and bed expansion is planned across FY27-FY30 with ~60% from brownfield projects. The North Bangalore hospital is expected to reach monthly break-even this year, with losses projected to decline from their Q1 peak.

powered bylight_fuzz_icon
47665872

*this image is generated using AI for illustrative purposes only.

HealthCare Global Enterprises Limited has released the transcript of its earnings call for Q1 FY27, providing investors and analysts with management's detailed commentary on the company's financial performance and strategic direction for the quarter ended June 30, 2026. The earnings call was conducted on August 07, 2026, following an earlier intimation dated July 27, 2026, and covered both standalone and consolidated figures.

Revenue and Margin Guidance

Management maintained a mid-teens revenue growth outlook, driven by contributions from both existing and new centers. The company has set clear EBITDA margin targets, aiming for 21-22% within the next two years and 25% within the next four to five years. The following table summarizes the key guidance parameters shared during the concall:

Parameter: Details
Revenue Growth Outlook: Mid-teens (existing and new centers)
EBITDA Margin Target (2 years): 21-22%
EBITDA Margin Target (4-5 years): 25%
Annual Maintenance CapEx: ~INR 100 crores
Marketing Spend (long-term): 2.50-2.60% of sales

Margin improvement is expected to be driven by a better payor mix, increased clinical complexity, reduced losses from new hospitals, and operating leverage as centers mature. Investment in clinical technology is also cited as a key enabler of the long-term margin trajectory.

Bed Expansion Plans

HealthCare Global Enterprises outlined a structured bed expansion roadmap spanning FY27 through FY30. Approximately 60% of the planned additions are from brownfield projects, which are expected to enable faster execution and lower capital expenditure compared to greenfield developments. The planned expansion is detailed below:

Period: Planned Bed Additions
FY27: 65 beds
FY28-FY29: 520 beds
FY30: 230 beds
Brownfield Share: ~60% of total expansion

North Bangalore Hospital Update

Management provided a specific update on the North Bangalore hospital, which is expected to achieve monthly break-even during the current year. The facility is projected to reach optimal utilization of 60-65% within three to four years of operation. Losses from this center, which peaked in Q1, are projected to decrease going forward, contributing positively to the overall margin improvement narrative shared by management.

Regulatory Compliance and Investor Access

The disclosure was made in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was submitted to the Compliance Departments of both the National Stock Exchange of India Limited and BSE Limited. The full audio recording of the earnings call is available on the company's official investor relations website, enabling stakeholders to access management's commentary on quarterly performance, payor mix trends, clinical complexity, and capital expenditure plans directly.

Historical Stock Returns for Healthcare Global Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
+1.45%+2.02%+5.67%+28.34%+2.78%0.0%

How might the shift towards a 60% brownfield expansion strategy impact the company's capital efficiency and time-to-market compared to historical greenfield projects?

What specific clinical technologies is HCG planning to invest in to drive the projected margin expansion from 21-22% to 25% over the next five years?

Given the North Bangalore hospital's path to break-even, what operational metrics will indicate if it achieves the targeted 60-65% utilization rate within the three-to-four-year window?

Healthcare Global Enterprises
View Company Insights
View All News
like17
dislike

HealthCare Global Enterprises Q1 Results: Net Profit Surges 175% YoY to ₹1,646 lakhs

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights

HealthCare Global Enterprises Limited reported consolidated net profit (after tax and exceptional items) of ₹1,646 lakhs for the quarter ended June 30, 2026, a sharp rise from ₹598 lakhs in the corresponding quarter ended June 30, 2025. Consolidated total income grew to ₹70,723 lakhs from ₹61,999 lakhs in the year-ago quarter. On a standalone basis, net profit stood at ₹558 lakhs against ₹345 lakhs in the corresponding quarter ended June 30, 2025, with standalone total income rising to ₹38,622 lakhs from ₹33,503 lakhs. The results were approved by the board of directors at their meeting held on August 06, 2026.

powered bylight_fuzz_icon
47716093

*this image is generated using AI for illustrative purposes only.

HealthCare Global Enterprises Limited reported a significant improvement in profitability for the quarter ended June 30, 2026, with consolidated net profit (after tax and exceptional items) rising to ₹1,646 lakhs from ₹598 lakhs in the corresponding quarter ended June 30, 2025. The results were reviewed by the audit committee and approved by the board of directors at their meeting held on August 06, 2026.

Consolidated Financial Performance

On a consolidated basis, total income for the quarter ended June 30, 2026 grew to ₹70,723 lakhs, compared to ₹61,999 lakhs in the corresponding quarter ended June 30, 2025, and ₹66,540 lakhs in the preceding quarter ended March 31, 2026. Net profit before tax and exceptional items stood at ₹2,503 lakhs for the quarter, compared to ₹1,192 lakhs in the year-ago quarter and ₹3,316 lakhs in the preceding quarter. No exceptional items were recorded in the quarter ended June 30, 2026, unlike the preceding quarter ended March 31, 2026, which had a net exceptional loss of ₹3,191 lakhs.

The net profit attributable to equity shareholders of the company on a consolidated basis was ₹1,377 lakhs for the quarter ended June 30, 2026, compared to ₹475 lakhs in the corresponding quarter ended June 30, 2025 and ₹217 lakhs in the preceding quarter ended March 31, 2026. Total comprehensive income attributable to equity shareholders stood at ₹1,424 lakhs for the quarter.

The following table summarises the consolidated financial results:

Metric: Q1 (30 Jun 2026) Unaudited Q4 (31 Mar 2026) Q1 (30 Jun 2025) Unaudited FY (31 Mar 2026) Audited
Total Income (₹ Lakhs): 70,723 66,540 61,999 257,040
Net Profit (before tax & exceptional items) (₹ Lakhs): 2,503 3,316 1,192 7,150
Exceptional Items (₹ Lakhs): - (3,191) - (4,458)
Net Profit (after tax & exceptional items) (₹ Lakhs): 1,646 404 598 2,278
Net Profit attributable to equity shareholders (₹ Lakhs): 1,377 217 475 1,376
Total Comprehensive Income attributable to equity shareholders (₹ Lakhs): 1,424 426 492 1,831
Equity Share Capital (₹ Lakhs): 14,930 14,930 13,942 14,930
Basic EPS (₹): 0.92 0.15 0.34 0.97
Diluted EPS (₹): 0.92 0.15 0.33 0.96

Standalone Financial Performance

On a standalone basis, HealthCare Global Enterprises reported total income of ₹38,622 lakhs for the quarter ended June 30, 2026, up from ₹33,503 lakhs in the corresponding quarter ended June 30, 2025 and ₹36,513 lakhs in the preceding quarter ended March 31, 2026. Net profit before tax and exceptional items was ₹748 lakhs, compared to ₹524 lakhs in the year-ago quarter. Net profit after tax and exceptional items stood at ₹558 lakhs, against ₹345 lakhs in the corresponding quarter ended June 30, 2025 and ₹153 lakhs in the preceding quarter ended March 31, 2026.

The following table summarises the standalone financial results:

Metric: Q1 (30 Jun 2026) Unaudited Q4 (31 Mar 2026) Q1 (30 Jun 2025) Unaudited FY (31 Mar 2026) Audited
Total Income (₹ Lakhs): 38,622 36,513 33,503 139,497
Net Profit (before tax & exceptional items) (₹ Lakhs): 748 3,857 524 6,500
Exceptional Items (₹ Lakhs): - (4,752) - (5,538)
Net Profit (after tax & exceptional items) (₹ Lakhs): 558 153 345 1,458
Net Profit attributable to equity shareholders (₹ Lakhs): 558 153 345 1,458
Total Comprehensive Income attributable to equity shareholders (₹ Lakhs): 558 142 345 1,466
Equity Share Capital (₹ Lakhs): 14,930 14,930 13,942 14,930
Basic EPS (₹): 0.37 0.11 0.25 1.03
Diluted EPS (₹): 0.37 0.11 0.24 1.03

Earnings Per Share

On a consolidated basis, basic and diluted earnings per share (of ₹10 each) for the quarter ended June 30, 2026 stood at ₹0.92 each, compared to ₹0.34 (basic) and ₹0.33 (diluted) in the corresponding quarter ended June 30, 2025. On a standalone basis, basic and diluted EPS for the quarter were ₹0.37 each, against ₹0.25 (basic) and ₹0.24 (diluted) in the year-ago quarter. The equity share capital remained unchanged at ₹14,930 lakhs for the quarter ended June 30, 2026, compared to ₹13,942 lakhs in the corresponding quarter ended June 30, 2025.

Notes and Disclosures

The financial results represent an extract from the detailed format of quarterly financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The figures for the preceding quarter ended March 31, 2026 are balancing figures between audited figures for the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditors. The full format of the quarterly financial results is available on the websites of NSE Limited, BSE Limited, and the company's website.

Historical Stock Returns for Healthcare Global Enterprises

1 Day5 Days1 Month6 Months1 Year5 Years
+1.45%+2.02%+5.67%+28.34%+2.78%0.0%

What specific operational or strategic initiatives drove the 175% year-over-year increase in consolidated net profit for Q1 FY2027?

How does the elimination of exceptional items in Q1 2026 compare to the significant losses recorded in Q4 2025, and what does this indicate about the company's financial stability?

Will management provide guidance on whether the current margin expansion is sustainable given the competitive landscape in the healthcare sector?

Healthcare Global Enterprises
View Company Insights
View All News
like16
dislike

More News on Healthcare Global Enterprises

1 Year Returns:+2.78%